Price movement over the last 24 hours
Alcon AG vs ARMOUR Residential REIT, Inc. — how do they compare? Alcon AG trades at $66.8 (market cap $32.69B), while ARMOUR Residential REIT, Inc. trades at $16.97 (market cap $2.11B). The key difference: Alcon AG is far larger — about 15.5× ARMOUR Residential REIT, Inc.'s market cap, and ARMOUR Residential REIT, Inc. pays the higher dividend (16.96%). Which is the better fit depends on your goals.
| ALC | ARR | |
|---|---|---|
Market Cap | $32.69B | $2.11B |
Sector | Health | Financials |
52-Week High | $92.22 | $19.12 |
52-Week Low | $62.02 | $14.05 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | 16.96% |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
ARR trades at $16.98, down 0.88% today, with a bullish technical signal from moving averages but neutral oscillators. The stock shows a low P/E of 6.9 and P/B of 0.91, with strong net income margin of 95.99% in 2025. Recent earnings beat expectations in Q1 2026, though Q3 and Q4 2025 missed. Dividend payments of $0.24 per share continue consistently, supporting income appeal amid mixed analyst sentiment.
Outlook is cautious with 60% hold ratings; consensus target is $18.50 offering ~9% upside. Risks include volatile cash flows from large investing activities and reliance on dividend sustainability. Institutional sentiment is divided, with Zacks rating it Strong Sell on June 23, 2026, contrasting with some bullish dividend coverage analyses.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →ARMOUR Residential REIT Inc is a real estate investment trust that invests in residential mortgage-backed securities or RMBS. These are issued or guaranteed by U.S.-government-sponsored enterprises, such as Fannie Mae, Freddie Mac, or Ginnie Mae. The company's investment portfolio is composed of mortgage-backed securities, adjustable-rate mortgage securities, and multifamily mortgage-backed securities. In terms of total fair value, most Armour's investments are long-term, fixed-rate agency RMBS. Multifamily RMBS also represents a substantial amount. Fannie Mae guarantees most of the company's holdings. Armour derives substantially all its revenue as interest income from its investments.
Read more on ARR →